RecruitingPhase 1NCT07204418

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants


Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Enrollment

56 participants

Start Date

Oct 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • Participant must be healthy male and female (INOCBP) participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (VS), and clinical laboratory determinations.
  • Participant must be a normal/extensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer.
  • Participant must have body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive.

Exclusion Criteria1

  • Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population reference ranges.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXanomeline/ Trospium Chloride

Specified dose on specified days


Locations(3)

Anaheim Clinical Trials

Anaheim, California, United States

ICON - Lenexa

Lenexa, Kansas, United States

ICON Development Solutions

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07204418


Related Trials